Incidence and characteristics of pseudoprogression in IDH-mutant high-grade gliomas: A POLA network study.
IDH-mutant
chemotherapy
high-grade glioma
pseudoprogression
radiotherapy
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
14 03 2023
14 03 2023
Historique:
pubmed:
12
8
2022
medline:
17
3
2023
entrez:
11
8
2022
Statut:
ppublish
Résumé
Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described. We analyzed pseudoprogression characteristics and explored the possibility of pseudoprogression misdiagnosis in IDHmt HGG patients, treated with radiotherapy (RT) (with or without chemotherapy [CT]), included in the French POLA network. Pseudoprogression was analyzed in patients with MRI available for review (reference cohort, n = 200). Pseudoprogression misdiagnosis was estimated in this cohort and in an independent cohort (control cohort, n = 543) based on progression-free survival before and after first progression. In the reference cohort, 38 patients (19%) presented a pseudoprogression after a median time of 10.5 months after RT. Pseudoprogression characteristics were similar across IDHmt HGG subtypes. In most patients, it consisted of the appearance of one or several infracentimetric, asymptomatic, contrast-enhanced lesions occurring within 2 years after RT. The only factor associated with pseudoprogression occurrence was adjuvant PCV CT. Among patients considered as having a first true progression, 7 out of 41 (17%) in the reference cohort and 35 out of 203 (17%) in the control cohort were retrospectively suspected to have a misdiagnosed pseudoprogression. Patients with a misdiagnosed pseudoprogression were characterized by a time to event and an outcome similar to that of patients with a pseudoprogression but presented with larger and more symptomatic lesions. In patients with an IDHmt HGG, pseudoprogression occurs later than in IDH-wildtype glioblastomas and seems not only frequent but also frequently misdiagnosed. Within the first 2 years after RT, the possibility of a pseudoprogression should be carefully considered.
Sections du résumé
BACKGROUND
Incidence and characteristics of pseudoprogression in isocitrate dehydrogenase-mutant high-grade gliomas (IDHmt HGG) remain to be specifically described.
METHODS
We analyzed pseudoprogression characteristics and explored the possibility of pseudoprogression misdiagnosis in IDHmt HGG patients, treated with radiotherapy (RT) (with or without chemotherapy [CT]), included in the French POLA network. Pseudoprogression was analyzed in patients with MRI available for review (reference cohort, n = 200). Pseudoprogression misdiagnosis was estimated in this cohort and in an independent cohort (control cohort, n = 543) based on progression-free survival before and after first progression.
RESULTS
In the reference cohort, 38 patients (19%) presented a pseudoprogression after a median time of 10.5 months after RT. Pseudoprogression characteristics were similar across IDHmt HGG subtypes. In most patients, it consisted of the appearance of one or several infracentimetric, asymptomatic, contrast-enhanced lesions occurring within 2 years after RT. The only factor associated with pseudoprogression occurrence was adjuvant PCV CT. Among patients considered as having a first true progression, 7 out of 41 (17%) in the reference cohort and 35 out of 203 (17%) in the control cohort were retrospectively suspected to have a misdiagnosed pseudoprogression. Patients with a misdiagnosed pseudoprogression were characterized by a time to event and an outcome similar to that of patients with a pseudoprogression but presented with larger and more symptomatic lesions.
CONCLUSION
In patients with an IDHmt HGG, pseudoprogression occurs later than in IDH-wildtype glioblastomas and seems not only frequent but also frequently misdiagnosed. Within the first 2 years after RT, the possibility of a pseudoprogression should be carefully considered.
Identifiants
pubmed: 35953421
pii: 6661438
doi: 10.1093/neuonc/noac194
pmc: PMC10013645
doi:
Substances chimiques
Isocitrate Dehydrogenase
EC 1.1.1.41
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
495-507Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Neuro Oncol. 2019 Sep 6;21(9):1118-1130
pubmed: 30828724
Rev Neurol (Paris). 2019 Oct;175(9):534-543
pubmed: 31208813
Neuro Oncol. 2018 Jun 18;20(7):994-1002
pubmed: 29244086
J Neurooncol. 2012 Jan;106(2):399-407
pubmed: 21858607
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Neuro Oncol. 2017 May 1;19(5):719-725
pubmed: 28453748
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Br J Cancer. 2020 May;122(11):1580-1589
pubmed: 32291392
Rev Neurol. 2015 Sep 1;61(5):225-32
pubmed: 26308844
J Neurooncol. 2017 Nov;135(2):371-379
pubmed: 28752498
J Neurooncol. 2015 May;123(1):141-50
pubmed: 25894594
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
CNS Oncol. 2019 Mar 1;8(1):CNS28
pubmed: 30806082
Neuro Oncol. 2014 Jan;16(1):123-30
pubmed: 24285548
J Neurooncol. 2019 Mar;142(1):69-77
pubmed: 30488294
Oncologist. 2020 Aug;25(8):e1221-e1232
pubmed: 32488924
J Neurooncol. 2017 Sep;134(3):495-504
pubmed: 28382534
Clin Neurol Neurosurg. 2016 Dec;151:31-36
pubmed: 27764705
Lancet Oncol. 2008 May;9(5):453-61
pubmed: 18452856
Radiother Oncol. 2020 Jan;142:36-42
pubmed: 31431375
J Neurooncol. 2009 Aug;94(1):97-101
pubmed: 19221865
J Neurooncol. 2016 Dec;130(3):529-533
pubmed: 27704386
Crit Rev Oncol Hematol. 2021 Jan;157:103188
pubmed: 33307200
Cancer. 2008 Jul 15;113(2):405-10
pubmed: 18484594
J Neurooncol. 2019 Mar;142(1):161-169
pubmed: 30604393
Clin Transl Radiat Oncol. 2018 Jan 12;9:30-34
pubmed: 29594248
N Engl J Med. 2015 Jun 25;372(26):2499-508
pubmed: 26061753
Semin Neurol. 2017 Oct;37(5):589-596
pubmed: 29207418
Neurooncol Pract. 2020 Mar;7(2):185-195
pubmed: 32626587
Expert Rev Neurother. 2017 Nov;17(11):1109-1115
pubmed: 28862482
Nat Rev Neurol. 2019 Jul;15(7):405-417
pubmed: 31227792
Neurooncol Pract. 2019 Jan;6(1):22-29
pubmed: 31385994
J Neurooncol. 2016 Aug;129(1):109-21
pubmed: 27180091
Int J Radiat Oncol Biol Phys. 2019 May 1;104(1):149-156
pubmed: 30684665
Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):1094-9
pubmed: 24267971
J Clin Oncol. 2010 Apr 10;28(11):1963-72
pubmed: 20231676
Neuro Oncol. 2019 May 6;21(5):669-677
pubmed: 30668823
Brain Tumor Pathol. 2013 Apr;30(2):67-72
pubmed: 22752663
Acta Neuropathol. 2015 May;129(5):679-93
pubmed: 25783747
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2015 Jun 25;372(26):2481-98
pubmed: 26061751
J Clin Oncol. 2008 May 1;26(13):2192-7
pubmed: 18445844